Single-use device prepares motile sperm for IVF, ICSI and IUI, giving fertility labs the next evolution in sperm separation technology with advanced capabilities.
A simple vaginal swab may one day help women with abnormal bleeding learn whether they have endometrial cancer without first going through a painful biopsy.
An AI model created by researchers at King’s can detect signs of faulty repair mechanisms in ovarian cancer cells, potentially leading to a low-cost, widely accessible diagnostic tool in the future.
A new blood test that could lead to earlier detection and treatment of breast cancer.
Exposure to hormone-disrupting chemicals may leave molecular changes that could someday help identify people at higher risk of breast cancer
A research team led by professor Chan Kui-ming from the Department of Biomedical Sciences at CityUHK discovered that H2BE113K, a missense H2B mutation, promotes colony formation and lung metastasis in breast cancer.
Women struggling to secure answers for suspected endometriosis and PMOS could be given stronger evidence of their symptoms through wearable technology shaped by its founder’s own lived experience. WombWise, founded by Edinburgh Napier University graduate Emily Youngs, has been crowned winner of the Create Change Challenge at the Converge Awards.
Argus’s Neurora tool is intended to complement clinicians’ professional judgement rather than serve as a standalone diagnostic for autism.
Researchers at the Icahn School of Medicine at Mount Sinai have developed an artificial intelligence (AI) approach that uses data from wearable devices to forecast upcoming periods of prolonged sitting in women with chronic pelvic pain disorders.
U.S. FDA Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) underscore UTRxMYCN M1-14’s therapeutic targeting of the “undruggable” MYCN (N-MYC) in rare, aggressive soft tissue sarcomas, addressing a significant unmet clinical need in pediatric and adult sarcomas.